Characterization of a new SARS-CoV-2 variant that emerged in Brazil.
Characterization of a new SARS-CoV-2 variant that emerged in Brazil.
复制标题
DOI：
10.1073/pnas.2106535118
复制
发表时间：
2021-07-06
影响因子：
11.1
通讯作者：
Kawaoka Y
中科院分区：
文献类型：
--
作者：
Imai M;Halfmann PJ;Yamayoshi S;Iwatsuki-Horimoto K;Chiba S;Watanabe T;Nakajima N;Ito M;Kuroda M;Kiso M;Maemura T;Takahashi K;Loeber S;Hatta M;Koga M;Nagai H;Yamamoto S;Saito M;Adachi E;Akasaka O;Nakamura M;Nakachi I;Ogura T;Baba R;Fujita K;Ochi J;Mitamura K;Kato H;Nakajima H;Yagi K;Hattori SI;Maeda K;Suzuki T;Miyazato Y;Valdez R;Gherasim C;Furusawa Y;Okuda M;Ujie M;Lopes TJS;Yasuhara A;Ueki H;Sakai-Tagawa Y;Eisfeld AJ;Baczenas JJ;Baker DA;O'Connor SL;O'Connor DH;Fukushi S;Fujimoto T;Kuroda Y;Gordon A;Maeda K;Ohmagari N;Sugaya N;Yotsuyanagi H;Mitsuya H;Suzuki T;Kawaoka Y
严重急性呼吸综合征冠状病毒2 （SARS-CoV-2）变体令人担忧，其中P.1变体在巴西占主导地位。巴西目前的死亡人数创历史新高。在这里，我们报告了P.1变异在仓鼠中的致病性与非变异SARS-CoV-2相似。然而，从其在小鼠中的复制可以看出，它的宿主范围扩大了。先前感染非变异SARS-CoV-2菌株可有效阻止P.1变异在下呼吸道再次感染的仓鼠中复制。非变异感染患者的恢复期血清或信使RNA疫苗接种者的血清在p1和以前流行的毒株中显示出相当的中和效价。这些结果表明，以前的SARS-CoV-2感染和基于原始SARS-CoV-2的疫苗将对p - 1感染提供一定的保护。严重急性呼吸综合征冠状病毒2 （SARS-CoV-2）的刺突(S)蛋白在病毒感染中起关键作用。它也是刺激宿主保护性免疫反应的主要抗原，特别是产生中和抗体。最近，在巴西出现了一种新的SARS-CoV-2变体，该变体具有S蛋白的多个突变，称为P.1。在这里，我们利用叙利亚仓鼠（一种成熟的用于研究SARS-CoV-2疾病（COVID-19）的小动物模型）对日本分离的P.1变异进行了表征。在仓鼠中，该变异显示出与早期和当代菌株相似的复制能力和致病性（即SARS-CoV-2在S蛋白614位含有天冬氨酸[D]或甘氨酸[G]）。恢复期患者和BNT162b2信使RNA疫苗接种者的血清和/或血浆在P.1变异体、S-614D和S-614G株中显示出相当的中和效价。相比之下，p - 1感染患者的血清对S-614D和S-614G菌株的识别程度不如p - 1变体。先前感染S-614D或S-614G菌株的仓鼠在再次感染后可有效阻止P.1变异在下呼吸道复制。此外，将中和抗体被动转移到感染P.1变异体或S-614G株的仓鼠体内，可减少病毒在下呼吸道的复制。然而，与S-614G菌株相比，对P.1变种的影响不那么明显。这些发现表明，P.1变异可能在抗原性上与早期和当代SARS-CoV-2株有所不同。
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants are of concern, with the P.1 variants dominating in Brazil. Brazil is now seeing a record number of deaths. Here, we report that the pathogenicity in hamsters of a P.1 variant is similar to that of nonvariant SARS-CoV-2. However, it has an expanded host range as shown by its replication in mice. Prior infection with nonvariant SARS-CoV-2 strains efficiently prevented replication of the P.1 variant in the lower respiratory tract of hamsters upon reinfection. Convalescent sera from patients infected with nonvariants or sera from messenger RNA vaccinees showed comparable neutralization titers among the P.1 and previously circulating strains. These results suggest that previous SARS-CoV-2 infection and vaccines based on the original SARS-CoV-2 will provide some protection against P.1 infection. The spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) plays a key role in viral infectivity. It is also the major antigen stimulating the host's protective immune response, specifically, the production of neutralizing antibodies. Recently, a new variant of SARS-CoV-2 possessing multiple mutations in the S protein, designated P.1, emerged in Brazil. Here, we characterized a P.1 variant isolated in Japan by using Syrian hamsters, a well-established small animal model for the study of SARS-CoV-2 disease (COVID-19). In hamsters, the variant showed replicative abilities and pathogenicity similar to those of early and contemporary strains (i.e., SARS-CoV-2 bearing aspartic acid [D] or glycine [G] at position 614 of the S protein). Sera and/or plasma from convalescent patients and BNT162b2 messenger RNA vaccinees showed comparable neutralization titers across the P.1 variant, S-614D, and S-614G strains. In contrast, the S-614D and S-614G strains were less well recognized than the P.1 variant by serum from a P.1-infected patient. Prior infection with S-614D or S-614G strains efficiently prevented the replication of the P.1 variant in the lower respiratory tract of hamsters upon reinfection. In addition, passive transfer of neutralizing antibodies to hamsters infected with the P.1 variant or the S-614G strain led to reduced virus replication in the lower respiratory tract. However, the effect was less pronounced against the P.1 variant than the S-614G strain. These findings suggest that the P.1 variant may be somewhat antigenically different from the early and contemporary strains of SARS-CoV-2.
登录
查看更多内容
影响因子：
7.7
作者：
Weisblum Y;Schmidt F;Zhang F;DaSilva J;Poston D;Lorenzi JC;Muecksch F;Rutkowska M;Hoffmann HH;Michailidis E;Gaebler C;Agudelo M;Cho A;Wang Z;Gazumyan A;Cipolla M;Luchsinger L;Hillyer CD;Caskey M;Robbiani DF;Rice CM;Nussenzweig MC;Hatziioannou T;Bieniasz PD
通讯作者：
Bieniasz PD
DOI：
10.1126/science.abc4730
发表时间：
2020-09-25
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Gu H;Chen Q;Yang G;He L;Fan H;Deng YQ;Wang Y;Teng Y;Zhao Z;Cui Y;Li Y;Li XF;Li J;Zhang NN;Yang X;Chen S;Guo Y;Zhao G;Wang X;Luo DY;Wang H;Yang X;Li Y;Han G;He Y;Zhou X;Geng S;Sheng X;Jiang S;Sun S;Qin CF;Zhou Y
通讯作者：
Zhou Y
DOI：
10.1126/science.abe8499
发表时间：
2020-12-18
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Hou YJ;Chiba S;Halfmann P;Ehre C;Kuroda M;Dinnon KH 3rd;Leist SR;Schäfer A;Nakajima N;Takahashi K;Lee RE;Mascenik TM;Graham R;Edwards CE;Tse LV;Okuda K;Markmann AJ;Bartelt L;de Silva A;Margolis DM;Boucher RC;Randell SH;Suzuki T;Gralinski LE;Kawaoka Y;Baric RS
通讯作者：
Baric RS
影响因子：
5.6
作者：
Villoutreix BO;Calvez V;Marcelin AG;Khatib AM
通讯作者：
Khatib AM
影响因子：
64.8
作者：
Dinnon KH 3rd;Leist SR;Schäfer A;Edwards CE;Martinez DR;Montgomery SA;West A;Yount BL Jr;Hou YJ;Adams LE;Gully KL;Brown AJ;Huang E;Bryant MD;Choong IC;Glenn JS;Gralinski LE;Sheahan TP;Baric RS
通讯作者：
Baric RS